Health Care & Life Sciences » Biotechnology | Aimmune Therapeutics Inc.

Aimmune Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
9.00
29.00
115.00
534.00
966.00
1,598
Gross Income
9.00
29.00
115.00
534.00
966.00
1,598
SG&A Expense
4,749.00
11,103.00
35,882.00
80,993.00
132,308.00
213,743
EBIT
4,758.00
11,132.00
35,997.00
81,527.00
133,274.00
215,341
Non Operating Income/Expense
-
-
36.00
-
-
-
Interest Expense
91.00
-
-
-
-
-
Pretax Income
4,825.00
11,120.00
35,816.00
80,824.00
131,269.00
210,691
Income Tax
-
-
-
-
56.00
61
Consolidated Net Income
4,825.00
11,120.00
35,816.00
80,824.00
131,325.00
210,752
Net Income
4,825.00
11,120.00
35,816.00
80,824.00
131,325.00
210,752
Net Income After Extraordinaries
4,825.00
11,120.00
35,816.00
80,824.00
131,325.00
210,752
Net Income Available to Common
4,825.00
11,120.00
35,816.00
80,824.00
131,325.00
210,752
EPS (Basic)
0.12
0.28
1.88
1.89
2.61
3.67
Basic Shares Outstanding
40,262.90
40,262.90
19,041.10
42,751.00
50,401.00
57,403
EPS (Diluted)
0.12
0.28
1.88
1.89
2.61
3.67
Diluted Shares Outstanding
40,262.90
40,262.90
19,041.10
42,751.00
50,401.00
57,403
EBITDA
4,749.00
11,103.00
35,882.00
80,993.00
132,308.00
213,743
Non-Operating Interest Income
24.00
12.00
217.00
703.00
2,005.00
4,650

About Aimmune Therapeutics

View Profile
Address
8000 Marina Boulevard
Brisbane California 94005
United States
Employees -
Website http://www.aimmune.com
Updated 07/08/2019
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.